Table 2.
Serum status of H pylori and CagA in cancer patients and control n (%)
|
Cancer |
Control |
|||||||
| Oral SCC | Esophageal SCC | Gastric cardia adenocarcinoma | Gastric non-cardia adenocarcinoma | Colon adenocarcinoma | 1st hospital-based control | 2nd hospital-based control | Community-based control | |
| n | 199 | 317 | 29 | 167 | 240 | 305 | 403 | 395 |
| H pylori | ||||||||
| - | 104 (52.3) | 205 (64.7) | 8 (27.6) | 48 (28.7) | 105 (43.8) | 141 (46.2) | 164 (40.7) | 235 (59.5) |
| + | 95 (47.7) | 112 (35.3) | 21 (72.4) | 119 (71.3) | 135 (56.3) | 164 (53.8) | 239 (59.3) | 160 (40.5) |
| CagA1 | ||||||||
| - | 14 (14.7) | 8 (7.3) | 1 (4.8) | 9 (7.6) | 12 (8.9) | 24 (14.6) | - | 11 (6.9) |
| ± | 13 (13.7) | 10 (9.2) | 3 (14.3) | 8 (6.8) | 7 (5.2) | 14 (8.5) | - | 6 (3.8) |
| + | 68 (71.6) | 91 (83.5) | 17 (81.0) | 101 (85.6) | 116 (85.9) | 126 (76.8) | - | 142 (89.0) |
1
CagA status was determined among the subjects with H pylori seropositivity (No CagA data was available in 3 esophageal SCC, 1 gastric non-cardia adenocarcinoma and 1 community-based control).